2011 was a busy year and biosimilars was the hot topic of the year for GaBI Online.
Top 10 most read GaBI Online articles in 2011
Home/Pharma News
|
Posted 30/03/2012
0
Post your comment
To ensure that none of GaBI Online’s readers have missed out on what happened in 2011, below is a list of the top 10 most read articles in 2011. Follow the links in the titles of each article to remind you what happened over the last year.
*arranged in top 10 order with the most read article listed first
This shows that guidelines are the issues of most interest, followed by a general interest in news and current status around biosimilars development, for instance, opportunities, challenges and approval status around the globe (Brazil, China, Europe). Needless to say, scientific research data is one of the most popular articles within GaBI Online.
If you are interested in contributing a research article in a similar area to GaBI Journal, please send us your submission here.
GaBI’s mission – building trust in cost-effective treatments
Editor’s comment
What do you think about GaBI Online providing overviews of this type? Please feel free to share your thoughts via email or in the comments section below. What other overviews would you like to see?
Guidelines
Brazil's ANVISA updates guidance on pharmacokinetic studies for biosimilars
Canada eliminates phase III trial requirement for biosimilar approvals
Policies & Legislation
ANVISA and DINAVISA sign MoU to strengthen border surveillance and regulatory cooperation
Congress pushes biosimilar bills as interchangeability concerns linger
Most viewed articles
The best selling biotechnology drugs of 2008: the next biosimilars targets
Global biosimilars guideline development – EGA’s perspective
Related content
Biosimilar race: Sandoz expands pipeline with Henlius, Teva secures ocrelizumab candidate
Sun Pharma completes $11.75bn financing syndication for Organon acquisition
Sun Pharma's Organon deal set to reshape biosimilars competitive landscape
Amgen expansion, BioNTech retrenchment highlight diverging manufacturing strategies in biopharma
Biosimilar race: Sandoz expands pipeline with Henlius, Teva secures ocrelizumab candidate
Home/Pharma News Posted 02/09/2026
Sun Pharma completes $11.75bn financing syndication for Organon acquisition
Home/Pharma News Posted 20/08/2026
Sun Pharma's Organon deal set to reshape biosimilars competitive landscape
Home/Pharma News Posted 12/06/2026
Amgen expansion, BioNTech retrenchment highlight diverging manufacturing strategies in biopharma
Home/Pharma News Posted 05/06/2026
The best selling biotechnology drugs of 2008: the next biosimilars targets
Post your comment